From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
Clinical data
AHFS/ Micromedex Detailed Consumer Information
  • AU: B1
  • US: C (Risk not ruled out)
  • US: Discontinued
Pharmacokinetic data
Protein binding Variable, 92–97% at therapeutic concentrations
Metabolism Hydrolyzed to clofibric acid; hepatic glucuronidation
Half-life Highly variable; average 18–22 hours. Prolonged in renal failure
Excretion Renal, 95 to 99%
637-07-0 YesY
PubChem CID 2796
DrugBank DB00636 YesY
ChemSpider 2694 YesY
KEGG D00279 YesY
Chemical data
Formula C12H15ClO3
242.698 g/mol
Physical data
Boiling point 148 °C (298 °F)
 YesY (what is this?)  (verify)

Clofibrate (tradename Atromid-S) is an organic compound. It is marketed as a fibrate. It is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.

Complications and controversies[edit]

It can induce SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH (vasopressin).

The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".[1]

Clofibrate was discontinued in 2002 due to adverse affects.


  1. ^ "WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators". Lancet 2 (8403): 600–4. September 1984. PMID 6147641.